Supplement: Families in Crisis

Families in Crisis Stanley M. Finger The impact of an autoimmune disease is felt by more than just the patient. One of the myths about autoimmune disease is that it has little socioeconomic impact. Nothing could be further from the truth. Autoimmune diseases as a whole afflict many people. In 2005, the National Institutes of Health estimated that as many as 24 million Americans have one or more a

Written byStanley M. Finger
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

One of the myths about autoimmune disease is that it has little socioeconomic impact. Nothing could be further from the truth.

Autoimmune diseases as a whole afflict many people. In 2005, the National Institutes of Health estimated that as many as 24 million Americans have one or more autoimmune disease. This lies between the number of people with cancer (about 10 million) and cardiovascular diseases (about 31 million). Roughly one million new cases of autoimmune disease are diagnosed every year in the United States.

In addition to those demographics, these diseases inflict high medical costs on patients. In 2001, NIH estimated the costs for autoimmune-disease treatments at over $100 billion per year, which is comparable to cancer ($74 billion) and cardiovascular diseases (about $100 billion). The costs of treating autoimmune diseases will surely grow. Some of today's best autoimmune treatments cost as much as $16,000 a year; multiplying that cost ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies